This Article Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McKenzie, M R Articles by Podgorsak, E B Search for Related Content PubMed PubMed Citation Articles by McKenzie, M R Articles by Podgorsak, E B

Clinical experience with electron pseudoarc therapy

Department of Oncology (Division of Radiation Oncology), McGill University, Montréal, Québec, Canada

Between November 1986 and June 1990, 24 patients were treated with electron pseudoarc therapy at McGill University. There were 21 females and three males aged 27 to 81 years (median 62 years). 17 patients, nine of whom had received previous conventional locoregional irradiation, were treated palliatively for locally extensive breast carcinoma. Eight of these 17 patients achieved a complete, and six a partial, response to treatment; nine subsequently developed evidence of progressive disease within the treatment field after intervals of one to 27 months (median 5 months) following therapy. Eight patients developed moist desquamation of the treated chest wall, which was extensive in four; one of these patients developed chronic ulceration of the skin. The latter and one additional patient developed radiation pneumonitis. Seven patients were treated with radical intent, two following mastectomy for breast carcinoma, and one each for chest wall lymphoma, chest wall sarcoma, scalp angiosarcoma, scalp lymphoma and posterior cervical soft tissue sarcoma. Local control was achieved in six of these seven patients with minimal toxicity. Electron pseudoarc therapy is a treatment option for selected breast carcinoma patients for palliation of extensive chest wall disease, although morbidity may be considerable. The technique may, however, play a more useful role in other situations where the superficial portion of large curved surfaces is to be treated with curative intent.

^* Dr McKenzie is a McEachern Fellow of The Canadian Cancer Society.

Received for publication May 8, 1992. Revision received September 14, 1992. Accepted for publication September 28, 1992.

This article has been cited by other articles:

				R. Nakamura, S. Harada, T. Obara, S. Ehara, A. Yoshida, T. Akasaka, and M. Shozushima Iridium-192 Brachytherapy for Hemorrhagic Angiosarcoma of the Scalp: a Case Report Jpn. J. Clin. Oncol., April 1, 2003; 33(4): 198 - 201. [Abstract] [Full Text] [PDF]